CN113350296B - PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof - Google Patents
PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof Download PDFInfo
- Publication number
- CN113350296B CN113350296B CN202110652104.0A CN202110652104A CN113350296B CN 113350296 B CN113350296 B CN 113350296B CN 202110652104 A CN202110652104 A CN 202110652104A CN 113350296 B CN113350296 B CN 113350296B
- Authority
- CN
- China
- Prior art keywords
- chitosan
- sequence peptide
- pad4 inhibitor
- crgd
- crgdv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 115
- 229940122298 Peptidyl arginine deiminase IV inhibitor Drugs 0.000 title claims abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 5
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 25
- 239000003960 organic solvent Substances 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 19
- 238000006845 Michael addition reaction Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 abstract description 28
- 210000004027 cell Anatomy 0.000 abstract description 19
- 230000008685 targeting Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 24
- 238000003917 TEM image Methods 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000002329 infrared spectrum Methods 0.000 description 18
- CCYFIZIEAFRYKT-LJQANCHMSA-N 9h-fluoren-9-ylmethyl n-[(2s)-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C=O)C3=CC=CC=C3C2=C1 CCYFIZIEAFRYKT-LJQANCHMSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000012295 chemical reaction liquid Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 11
- 238000010532 solid phase synthesis reaction Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000008034 disappearance Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 239000002105 nanoparticle Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229960004050 aminobenzoic acid Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007822 coupling agent Substances 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 3
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 3
- VPWIPOVMGVVQON-UHFFFAOYSA-N 4-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]benzoic acid Chemical compound CC(C)(C)OC(=O)C1=CC(N)=CC=C1C(O)=O VPWIPOVMGVVQON-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000012351 deprotecting agent Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- QYYCZJUFHDLLOJ-AWEZNQCLSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCNC(=O)OCC1=CC=CC=C1 QYYCZJUFHDLLOJ-AWEZNQCLSA-N 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 2
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 2
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- VHJCEPCKDNEGPR-UHFFFAOYSA-N CC(C)(C)OC(C(C=C(C=C1)N)=C1C(OC)=O)=O Chemical compound CC(C)(C)OC(C(C=C(C=C1)N)=C1C(OC)=O)=O VHJCEPCKDNEGPR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101150094373 Padi4 gene Proteins 0.000 description 2
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- BGWMHFKCAUBYJJ-UHFFFAOYSA-N ethyl 2-chloroethanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CCl BGWMHFKCAUBYJJ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AAAFQLPJNOITCL-SFHVURJKSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 AAAFQLPJNOITCL-SFHVURJKSA-N 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BHURDHFNHSMHFP-UHFFFAOYSA-N CC(C)(C)OC(=O)OC(=O)C1=CC=C(N)C=C1 Chemical compound CC(C)(C)OC(=O)OC(=O)C1=CC=C(N)C=C1 BHURDHFNHSMHFP-UHFFFAOYSA-N 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- WVZWEMOFSIEEMU-UHFFFAOYSA-N indene-1,2,3-trione Chemical compound C1=CC=C2C(=O)C(=O)C(=O)C2=C1 WVZWEMOFSIEEMU-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan, a preparation method and application thereof, belonging to the technical field of antitumor drugs. The CRGD sequence peptide modified chitosan is used as a drug carrier, wherein the chitosan has good biocompatibility and biodegradability, the RGD sequence peptide in the CRGD sequence peptide can be specifically combined on a corresponding receptor over-expressed by a target cell, and the targeting effect achieved by targeting drug delivery to a target region can be achieved by utilizing the specific combination of the receptor on the surface of a tumor cell and a ligand of a targeting preparation. According to the invention, the PAD4 inhibitor is loaded by using CRGD sequence peptide modified chitosan, so that the selectivity of the PAD4 inhibitor on target tumor cells can be enhanced, adverse drug reactions are reduced, and the PAD4 inhibitor has good antitumor activity.
Description
Technical Field
The invention relates to the technical field of antitumor drugs, and particularly relates to a PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan, and a preparation method and application thereof.
Background
Cancer is a leading disease of death in a large part of the world, cancer cells are not growing in a controlled manner, nutrients drawn from host organisms can grow and reproduce indefinitely, and the variety of cancer cells is very diverse, thus making treatment of cancer very challenging.
The polypeptide arginine deiminase 4 (PAD 4) is one of the important targets of cancer. PAD4 is used as adjuvant inhibitor of p53 and can inhibit the expression of cancer suppressor genes (such as p21/CDKN1A and GADD45) together with histone deacetylase HDAC 2. PAD4 has lower bioavailability.
To improve the bioavailability of a drug, it is common practice to deliver the drug using a drug carrier. As far as today, there are many more mature drug carriers, including water-soluble high molecular weight polymer carriers, polymer nanoparticles, polymer micelles, dendrimers, liposomes, viral particles, carbon nanotubes, and graphene oxide, etc., however, the active targeting of these carriers is often not high.
Disclosure of Invention
In view of the above, the invention aims to provide a PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan, and a preparation method and application thereof, and the PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan provided by the invention has good active targeting property and antitumor activity.
In order to achieve the purpose of the invention, the invention provides the following technical scheme:
the invention provides a PAD4 inhibitor loaded on CRGD sequence peptide modified chitosan, which comprises a CRGD sequence peptide modified chitosan carrier and a PAD4 inhibitor loaded on the surface of the CRGD sequence peptide modified chitosan carrier;
the cysteine in the CRGD sequence peptide is connected to the chitosan surface through acryloyl chloride.
Preferably, the CRGD sequence peptide includes one or more of CRGDV, CRGDs and CRGDF.
Preferably, the PAD4 inhibitor comprises one or more of PAD4 inhibitor 4B, PAD4 inhibitor 3B, PAD4 inhibitor 3B-OH.
Preferably, the PAD4 inhibitor in the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan has a loading amount of 12-18 wt%.
The invention provides a preparation method of the PAD4 inhibitor loaded on the CRGD sequence peptide modified chitosan, which comprises the following steps:
(1) mixing chitosan, acryloyl chloride, a first acid-binding agent and a first organic solvent, and carrying out nucleophilic substitution reaction to obtain acryloyl chloride modified chitosan;
(2) mixing the chitosan modified by acryloyl chloride, the CRGD sequence peptide, a second acid-binding agent and a second organic solvent, and carrying out Michael addition reaction to obtain a CRGD sequence peptide modified chitosan carrier;
(3) and stirring and mixing the CRGD sequence peptide modified chitosan carrier, the PAD4 inhibitor and a third organic solvent to obtain the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan.
Preferably, the molar ratio of the chitosan to the acryloyl chloride is 1.5-3: 1, and the molar ratio of the chitosan to the CRGD sequence peptide is 1-2: 1.8.
Preferably, the molar ratio of the chitosan to the PAD4 inhibitor is 1: 1-5.
Preferably, the time of the nucleophilic substitution reaction is 12-24 h.
Preferably, the time of the Michael addition reaction is 12-24 h.
The invention provides application of the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan in preparation of antitumor drugs.
The PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan is characterized in that the CRGD sequence peptide modified chitosan is used as a drug carrier, wherein the chitosan has good biocompatibility and biodegradability, the RGD sequence peptide in the CRGD sequence peptide can be specifically combined on a corresponding receptor overexpressed by a target cell, and the targeting effect achieved by targeting drug delivery to a target region can be achieved by utilizing the specific combination of the receptor on the surface of a tumor cell and a ligand of a targeting preparation. According to the invention, PAD4 inhibitor is loaded by using CRGD sequence peptide modified chitosan, so that the selectivity of PAD4 inhibitor to target tumor cells can be enhanced, adverse drug reactions can be reduced, and the PAD4 inhibitor has good antitumor activity. The results of the examples show that the CRGD sequence peptide modified chitosan loaded PAD4 inhibitor provided by the invention has good anti-tumor effect through activity evaluation.
The invention provides a preparation method of the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan, which is simple to operate and easy to realize industrial batch production.
Drawings
FIG. 1 is a schematic structural diagram of CRGD sequence peptide modified chitosan loaded PAD4 inhibitor;
FIG. 2 is an infrared spectrum of chitosan;
FIG. 3 is an infrared spectrum of chitosan-CRGDV;
FIG. 4 is an infrared spectrum of chitosan-CRGDF;
FIG. 5 is an infrared spectrum of chitosan-CRGDS;
FIG. 6 is an infrared spectrum of FIG. 4B;
FIG. 7 is an infrared spectrum of CRGDV-chitosan-4B;
FIG. 8 is an infrared spectrum of FIG. 8B;
FIG. 9 is an infrared spectrum of CRGDV-chitosan-3B;
FIG. 10 is an infrared spectrum of 3B-OH;
FIG. 11 is an infrared spectrum of CRGDV-chitosan-3B-OH;
FIG. 12 shows the preparation of chitosan1H NMR chart;
FIG. 13 is a drawing of chitosan-acryloyl chloride1H NMR chart;
FIG. 14 is a drawing of chitosan-CRGDV1A HNMR map;
FIG. 15 is of chitosan-CRGDF1H NMR chart;
FIG. 16 is a drawing of chitosan-CRGDS1H NMR chart;
FIG. 17 is a drawing of CRGDV-chitosan-4B1H NMR chart;
FIG. 18 is a drawing showing CRGDV-chitosan-3B1H NMR chart;
FIG. 19 is CRGDV-Chitosan-3B-OH1H NMR chart;
FIG. 20 is a transmission electron micrograph of chitosan;
FIG. 21 is a transmission electron micrograph of chitosan-CRGDV;
FIG. 22 is a transmission electron micrograph of chitosan-CRGDF;
FIG. 23 is a transmission electron micrograph of chitosan-CRGDS;
FIG. 24 shows chitosan-CRGDV: transmission electron micrograph of 1: 1;
FIG. 25 shows chitosan-CRGDV: transmission electron micrographs of 4B 1: 2;
FIG. 26 is a drawing of chitosan-CRGDV: transmission electron micrographs of 4B 1: 3;
FIG. 27 shows chitosan-CRGDV: transmission electron micrographs of 4B 1: 4;
FIG. 28 is chitosan-CRGDV: transmission electron micrograph of 1: 5;
fig. 29 is chitosan: transmission electron micrographs of 4B 1: 3;
FIG. 30 shows chitosan-CRGDV: transmission electron micrograph of 1: 3;
FIG. 31 is chitosan-CRGDV: transmission electron micrograph of 3B-OH ═ 1: 3;
FIG. 32 is a standard graph of 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl).
Detailed Description
The invention provides a PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan, which comprises a CRGD sequence peptide modified chitosan carrier and a PAD4 inhibitor loaded on the surface of the CRGD sequence peptide modified chitosan carrier;
the cysteine in the CRGD sequence peptide is linked to the chitosan surface via acryloyl chloride.
In the present invention, the CRGD sequence peptide preferably includes one or more of CRGDV, CRGDs and CRGDF. In the present invention, the CRGDV is cysteine-arginine-glycine-aspartic acid-valine, the CRGDS is cysteine-arginine-glycine-aspartic acid-phenylalanine, and the CRGDF is cysteine-arginine-glycine-aspartic acid-serine.
In the present invention, the PAD4 inhibitor preferably comprises one or more of PAD4 inhibitor 4B, PAD4 inhibitor 3B, PAD4 inhibitor 3B-OH. In the present invention, the PAD4 inhibitor 4B is(s) - (4- ((1- (benzylamino) -5- (2-chloroacetamide) -1-oxopentane-2-methyl) carbonyl) phenyl) boronic acid, and the PAD4 inhibitor 4B has the formula 1:
in the present invention, the PAD4 inhibitor 3B is(s) - (3- ((1- (benzylamino) -5- (2-chloroacetamide) -1-oxopentane-2-methyl) carbonyl) phenyl) boronic acid, and the PAD4 inhibitor 3B has the formula 2:
in the invention, the PAD4 inhibitor 3B-OH is(s) -4- ((2- (3-boron amide) -5- (2-chloroacetamide) pentanal) methyl) benzoic acid, and the PAD4 inhibitor 3B-OH has a structural formula shown in formula 3:
in the invention, the PAD4 inhibitor in the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan preferably has a loading amount of 12-18 wt%, and preferably 14.2 wt%.
The invention provides a preparation method of the PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan, which comprises the following steps:
(1) mixing chitosan, acryloyl chloride, a first acid-binding agent and a first organic solvent, and carrying out nucleophilic substitution reaction to obtain acryloyl chloride modified chitosan;
(2) mixing the chitosan modified by acryloyl chloride, the CRGD sequence peptide, a second acid-binding agent and a second organic solvent, and carrying out Michael addition reaction to obtain a CRGD sequence peptide modified chitosan carrier;
(3) and stirring and mixing the CRGD sequence peptide modified chitosan carrier, the PAD4 inhibitor and a third organic solvent to obtain the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan.
The method comprises the steps of mixing chitosan, acryloyl chloride, a first acid binding agent and a first organic solvent, and carrying out nucleophilic substitution reaction to obtain the acryloyl chloride modified chitosan. In the present invention, the first organic solvent is preferably N, N-dimethylformamide. In the present invention, the first acid scavenger is preferably triethylamine.
The invention has no special requirements on the type of the chitosan, and the chitosan which is generally sold in the market in the field can be used. In the invention, the molar ratio of the chitosan to the acryloyl chloride is preferably 1.5-3: 1, more preferably 2:1, and the molar ratio of the chitosan to the first acid-binding agent is preferably 1-2: 1.8. In the present invention, the acryloyl chloride is preferably added as a solution of acryloyl chloride in methylene chloride.
In the present invention, the mixing is preferably performed in the following manner: mixing chitosan, a first acid-binding agent and a first organic solvent, cooling to 0 ℃, and then dropwise adding a dichloromethane solution of acryloyl chloride.
In the invention, the nucleophilic substitution reaction is preferably carried out under the condition of stirring, the temperature of the nucleophilic substitution reaction is preferably room temperature, and the time is preferably 12-24 h, and more preferably 16-20 h. In the nucleophilic reaction process, the acryloyl chloride and amino or hydroxyl on the chitosan are subjected to nucleophilic substitution.
In the present invention, after the nucleophilic substitution reaction, the present invention preferably performs a post-treatment of the resulting nucleophilic substitution reaction liquid, the post-treatment preferably comprising the steps of:
and (3) sequentially dialyzing and freeze-drying the obtained nucleophilic substitution reaction liquid to obtain the acryloyl chloride modified chitosan solid. The dialysis is preferably carried out by using distilled water, and the cut-off molecular weight of the dialysis bag is 700-1000 Da during dialysis. In the present invention, the dialysis time is preferably 48 hours. The present invention does not require any particular means for lyophilization, and those well known to those skilled in the art can be used.
After the chitosan modified by the acryloyl chloride is obtained, the chitosan modified by the acryloyl chloride, the CRGD sequence peptide, a second acid-binding agent and a second organic solvent are mixed for Michael addition reaction to obtain the chitosan carrier modified by the CRGD sequence peptide.
In the present invention, the CRGD sequence peptide preferably includes one or more of CRGDV, CRGDs and CRGDF. In the present invention, the preparation method of CRGDV preferably comprises the following steps:
(1) soaking Fmoc-Val-Wang resin by using an organic solvent to obtain swelling Fmoc-Val-Wang resin;
(2) carrying out deprotection reaction on the swollen Fmoc-Val-Wang resin to obtain deprotected Fmoc-Val-Wang resin;
(3) mixing the deprotected Fmoc-Val-Wang resin, Fmoc-Asp (OtBu), a condensing agent and a coupling agent to perform solid-phase synthesis;
(4) repeating the steps (2) to (3) until the last amino acid is deprotected;
(5) and (4) mixing the product obtained in the step (4) with methanol, removing the methanol, and adding a cracking solution to perform cracking reaction to obtain the CRGDV.
The Fmoc-Val-Wang resin is soaked by using an organic solvent to obtain the swelling Fmoc-Val-Wang resin. In the present invention, the organic solvent is preferably anhydrous DMF; the swelling time is preferably 3-6 h.
The swelling Fmoc-Val-Wang resin is subjected to deprotection reaction to obtain the deprotected Fmoc-Val-Wang resin. In the present invention, it is preferable that the swollen Fmoc-Val-Wang resin is subjected to suction filtration under reduced pressure to remove the organic solvent before the deprotection reaction. In the present invention, the deprotection reagent is preferably anhydrous DMF and piperidine, and the volume ratio of the anhydrous DMF to the piperidine is preferably 4: 1. In the invention, the deprotection reaction is preferably carried out in two times, firstly, a deprotection reagent is added once, after shaking reaction is carried out for 3min, the deprotection reagent is removed by vacuum filtration, then, a deprotection reagent is added once, shaking reaction is carried out for 8min, and the deprotection reagent is removed by vacuum filtration. After removing the deprotection reagent, the invention preferably washes the deprotected Fmoc-Val-Wang resin, and the washing detergent is preferably anhydrous DMF and CH in sequence2Cl2And anhydrous DMF, the number of washing per detergent is preferably 2.
After the washing, the present invention preferably uses the indetrione method for detecting-NH2It is dark purple.
The deprotection Fmoc-Val-Wang resin, Fmoc-Asp (OtBu), a condensing agent and a coupling agent are mixed for solid phase synthesis. In the present invention, the condensing agent is preferably HBTU, the coupling agent is preferably anhydrous DMF and N-methylmorpholine, and the volume ratio of the anhydrous DMF to the N-methylmorpholine is preferably 95: 5. In the present invention, the time for the solid phase synthesis is preferably 45 min.
After the solid phase synthesis, the solid phase synthesis product is preferably washed, and the washing detergent is preferably anhydrous DMF and CH in sequence2Cl2And anhydrous DMF, the number of washing per detergent is preferably 2.
After the washing, the resin is preferably detected by an indetrione method, and is colorless and transparent.
The invention repeats steps (2) - (3) until the last amino acid is deprotected.
The product obtained in the step (4) is mixed with methanol, and after the methanol is removed, cracking liquid is added for cracking reaction to obtain CRGDV. In the present invention, the lysis solution is preferably trifluoroacetic acid: water: triisopropylsilane: 1, 2-ethanedithiol 92.5:2.5:2.5: 2.5. In the present invention, the cleavage reaction is preferably performed under ice bath conditions, and the time of the cleavage reaction is preferably 2.5.
In the present invention, after the cleavage reaction, it is preferable that the reaction solution obtained is filtered, and trifluoroacetic acid in the filtrate is blown dry with nitrogen. And adding glacial ethyl ether into the filtrate for washing, washing for three times, centrifuging and removing supernatant to obtain CRGDV.
In the present invention, the CRGDF is prepared in a similar manner to the CRGDV except that Fmoc-Val-Wang resin of step (1) is replaced with Fmoc-Val-Wang resin.
In the present invention, the CRGDS is prepared in a similar manner to the CRGDV except that Fmoc-Val-Wang resin of step (1) is replaced with Fmoc-Ser-Wang resin.
The preparation method comprises the steps of mixing the chitosan modified by acryloyl chloride, CRGD sequence peptide, triethylamine and a second organic solvent, and carrying out Michael addition reaction to obtain the CRGD sequence peptide modified chitosan carrier. In the present invention, the second organic solvent is preferably dimethyl sulfoxide and/or dioxane, and when the second organic solvent is dimethyl sulfoxide and dioxane, the volume ratio of dimethyl sulfoxide and dioxane is preferably 1:1. In the present invention, the second acid scavenger is preferably triethylamine.
In the present invention, the molar ratio of the chitosan to the CRGD-sequence peptide is preferably 1:1.8, and the molar ratio of the chitosan to the second acid scavenger is preferably 1: 0.7. In the invention, the Michael addition reaction is preferably carried out under the condition of stirring, the temperature of the Michael addition reaction is preferably room temperature, and the time is preferably 12-24 h, and more preferably 16-20 h. In the invention, the double bond of acryloyl chloride connected to chitosan in nucleophilic substitution reaction and cysteine side chain sulfhydryl in CRGD peptide chain produce Michael addition reaction.
In the present invention, after the michael addition reaction, the present invention preferably subjects the obtained michael addition reaction liquid to a post-treatment, which preferably comprises the steps of:
and (3) dialyzing and freeze-drying the obtained Michael addition reaction liquid in sequence to obtain the CRGD sequence peptide modified chitosan carrier solid. The dialysis is preferably carried out by using distilled water, and the cut-off molecular weight of the dialysis bag is 700-1000 Da during dialysis. In the present invention, the dialysis time is preferably 48 hours. The present invention does not require any particular means for lyophilization, and those well known to those skilled in the art can be used.
After the CRGD sequence peptide modified chitosan carrier is obtained, the CRGD sequence peptide modified chitosan carrier, the PAD4 inhibitor and a third organic solvent are stirred and mixed to obtain the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan. In the present invention, the PAD4 inhibitor preferably comprises one or more of PAD4 inhibitor 4B, PAD4 inhibitor 3B, PAD4 inhibitor 3B-OH. The source of the PAD4 inhibitor 4B, PAD4 inhibitor 3B, PAD4 inhibitor 3B-OH is not particularly critical to the present invention and may be prepared using any of the above materials that are conventionally commercially available in the art or by themselves.
In the present invention, the third organic solvent is preferably dimethyl sulfoxide and/or dioxane, and when the second organic solvent is dimethyl sulfoxide and dioxane, the volume ratio of dimethyl sulfoxide and dioxane is preferably 1:1.
In the invention, the molar ratio of the chitosan to the PAD4 inhibitor is preferably 1: 1-5, more preferably 1: 2-4, and further preferably 1: 3.
In the present invention, the temperature of the stirring and mixing is preferably room temperature, and the time is preferably 8 hours.
In the present invention, after the stirring and mixing, the present invention preferably performs a post-treatment of the obtained michael addition reaction liquid, and the post-treatment preferably comprises the steps of:
and (3) dialyzing and freeze-drying the obtained Michael addition reaction liquid in sequence to obtain the CRGD sequence peptide modified chitosan carrier solid. The dialysis is preferably carried out by using distilled water, and the cut-off molecular weight of the dialysis bag is 700-1000 Da during dialysis. In the present invention, the dialysis time is preferably 24 hours. The present invention does not require any particular means for such lyophilization, and lyophilization means well known to those skilled in the art may be used.
In the present invention, the structural schematic diagram of the CRGD sequence peptide-modified chitosan-loaded PAD4 inhibitor is shown in fig. 1.
The invention provides application of the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan in preparation of antitumor drugs.
The CRGD sequence peptide-modified chitosan-loaded PAD4 inhibitor provided by the present invention, and its preparation method and application are described in detail in the following examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Synthesis of (mono) CRGD sequence peptides
(1) Solid phase synthesis of CRGDV
1) Swelling: 300mg of Fmoc-Val-Wang resin was soaked in 10mL of anhydrous DMF for 3h in a solid phase synthesis tube to swell.
2) Deprotection: the anhydrous DMF was removed by suction filtration under reduced pressure, and 8 to 10mL of a deprotecting agent (anhydrous DMF: hexahydropyridine ═ 4:1) was added thereto, followed by shaking reaction for 3min, then the deprotecting agent was removed by suction filtration under reduced pressure, and 8 to 10mL of a deprotecting agent was added thereto, followed by shaking reaction for 8 min.
3) Washing: vacuum filtering to remove deprotection agent, sequentially adding anhydrous DMF and CH2Cl2And dry DMF washes with two washes of each solution.
4) Color development: indantrione method for detecting resin (detection-NH)2) It is dark purple.
5) Coupling: Fmoc-Asp (OtBu) and HBTU (condensation agent) were weighed, dissolved with a coupling agent (anhydrous DMF: N-methylmorpholine ═ 95:5), added to a solid phase synthesis tube, and reacted for 45min with shaking.
6) Washing: filtering under reduced pressure to remove coupling agent, sequentially adding anhydrous DMF and CH2Cl2And dry DMF washes with two washes of each solution.
7) Color development: the resin is detected by an indetrione method and is colorless and transparent.
Repeating the steps of 2-7 until the last amino acid is synthesized, and then carrying out deprotection.
8) Methanol shrinkage: methanol was added to the solid phase synthesis tube, the methanol was removed by suction filtration under reduced pressure, and this was repeated three times, and the resin was transferred to a 10mL reagent bottle.
9) Cracking: 3mL of a lysate (trifluoroacetic acid: water: triisopropylsilane: 1, 2-ethanedithiol: 92.5:2.5:2.5:2.5) was put into a reagent bottle, and the reaction was stirred in an ice-water bath for 2.5 hours. After the reaction is finished, filtering is carried out, and trifluoroacetic acid in the filtrate is blown dry by nitrogen. And then adding glacial ethyl ether into the filtrate for washing for three times, centrifuging and removing supernatant to obtain the CRGDV.
(2) Solid phase synthesis of CRGDF
The same preparation method as CRGDV is adopted, and 300mg of Fmoc-Phe-Wang resin is used as a raw material to obtain the CRGDF.
(3) Solid phase synthesis of CRGDS
The same preparation method as CRGDV is adopted, and 300mg Fmoc-Ser-Wang resin is used as a raw material to obtain CRGDS.
Synthesis of (II) PAD4 inhibitor
(1) Synthesis of 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl)
1) Preparation of Boc-Orn (Cbz) -NBzl:
Boc-Orn (Cbz) -OH 10mmol is dissolved in 20mL anhydrous Tetrahydrofuran (THF), 12mmol of N-hydroxybenzotriazole (HOBt) is added under ice bath condition to be completely dissolved, 12mmol of Dicyclohexylcarbodiimide (DCC) is slowly added, and stirring is carried out for 30min, thus obtaining reaction liquid A. Under the ice bath condition, 12mmol of benzylamine is dissolved in 20mL of anhydrous THF and added into the reaction liquid A, 1 mLN-methylmorpholine (NMM) is added, and the pH value is adjusted to 8-9. The mixture was stirred in ice bath for 1h and further stirred at room temperature for 48h, and TLC (chloroform: methanol ═ 20:1) showed disappearance of Boc-Orn (Cbz) -OH. Dicyclohexylurea (DCU) was filtered off and THF was distilled off under reduced pressure. The residue was dissolved in 50ml of Ethyl Acetate (EA), the solution obtained was in turn saturated NaHCO3Aqueous solution, saturated NaCl aqueous solution, 5% KHSO4Aqueous solution, saturated aqueous NaCl solution, saturated aqueous NaHCO solution3Washing with water solution and saturated NaCl water solution for three times, and treating ethyl acetate layer with anhydrous Na2SO4Drying, filtering under reduced pressure to remove the drying agent, and concentrating the filtrate under reduced pressure to dryness to obtain the compound Boc-Orn (Cbz) -NBzl.
2) Preparation of HCl. H-Orn (Cbz) -NBzl:
Boc-Orn (Cbz) -NBzl (10mmol) was dissolved with a small amount of dry ethyl acetate, and 4N HCl/EtOAc solution, TLC (EA: H) was added with stirring in an ice bath2O: HAc 4:1:2d) showed disappearance of the starting material spot, the solution was drained with a water pump, anhydrous ether was added, the reaction solution was again drained with a water pump, and the process was repeated three times to obtain HCl · H-orn (cbz) -NBzl.
3) Preparation of 4-carboxyphenylboronic acid-Orn (Cbz) -NBzl:
dissolving 10mmol of 4-carboxyphenylboronic acid in 20mL of anhydrous Tetrahydrofuran (THF), adding 12mmol of N-hydroxybenzotriazole (HOBt) under an ice bath condition, completely dissolving, slowly adding 12mmol of Dicyclohexylcarbodiimide (DCC), and stirring for 30min to obtain a reaction solution A. Under the ice-bath condition, 12mmol of HCl & H-Orn (Cbz) -NBzl is dissolved in 20mL of anhydrous THF and added into the reaction solution A, 1 mLN-methylmorpholine (NMM) is added, and the pH is adjusted to 8-9. Stirring in ice bathAfter 1h and stirring at rt for 48h, TLC (chloroform: methanol 20:1) showed disappearance of 4-carboxyphenylboronic acid. Dicyclohexylurea (DCU) was filtered off and THF was distilled off under reduced pressure. The residue was dissolved in 50ml of Ethyl Acetate (EA), and the resulting solution was successively treated with saturated aqueous NaHCO3 solution, saturated aqueous NaCl solution, 5% KHSO4Aqueous solution, saturated NaCl aqueous solution, saturated NaHCO3Washing the aqueous solution and saturated NaCl aqueous solution for three times, drying the ethyl acetate layer by using anhydrous Na2SO4, performing suction filtration under reduced pressure to remove the drying agent, and concentrating the filtrate under reduced pressure to be dry to obtain the compound 4-carboxyphenylboronic acid-Orn (Cbz) -NBzl.
4) Preparation of 4-carboxyphenylboronic acid-Orn-NBzl:
stirring and dissolving 4-carboxyphenylboronic acid-Orn (Cbz) -NBzl 10mmol by using a proper amount of methanol, adding a proper amount of Pd/C, keeping the reaction system sealed, pumping out air by using a tee joint, introducing hydrogen filled in an air bag, pumping out air by using the tee joint, repeatedly replacing the air in the reaction system, finally keeping the tee joint in a hydrogen introducing state, keeping a hydrogen environment at room temperature, stirring until a raw material point disappears, and monitoring by TLC. After the reaction is finished, the Pd/C is removed by filtering under reduced pressure, and the filtrate is concentrated to be dry under reduced pressure to obtain the compound 4-carboxyphenylboronic acid-Orn-NBzl.
5) Preparation of 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl):
4-Carboxyphenylboronic acid-Orn-NBzl 1mmol was dissolved in an appropriate amount of absolute methanol with stirring, and 5mmol of ethyl 2-chloroacetimidoate hydrochloride was added in an ice-water bath, and the pH was adjusted to 10 with N, N-Diisopropylethylamine (DIPEA). Stirring at room temperature for 12H, TLC (EA: H)2O: HAc ═ 4:1:2d) showed disappearance of 4-carboxyphenylboronic acid-Orn-NBzl, which was concentrated to dryness under reduced pressure and purified by C18 column chromatography to give 4B (4-carboxyphenylboronic acid-Orn (cl) -NBzl).
(2) Synthesis of 3B (3-carboxyphenylboronic acid-Orn (Cl) -NBzl)
3B (3-Carboxyphenylboronic acid-Orn (Cl) -NBzl) was obtained from 3-carboxyphenylboronic acid by the same method as that for 4B (4-Carboxyphenylboronic acid-Orn (Cl) -NBzl).
(3) Synthesis of 3B-OH (3-carboxyphenylboronic acid-Orn (Cl) -NBzl)
1) Preparation of 3-carboxyphenylboronic acid-Orn (Boc) -OBzl:
dissolving 10mmol of 3-carboxyphenylboronic acid in 20mL of sodium benzoateAdding 12mmol of N-hydroxybenzotriazole (HOBt) into Tetrahydrofuran (THF) in water under ice bath condition for complete dissolution, slowly adding 12mmol of Dicyclohexylcarbodiimide (DCC), and stirring for 30min to obtain reaction liquid A. Under the ice-bath condition, 12mmol of HCl & H-Orn (Boc) -OBzl is dissolved in 20mL of anhydrous THF and added into the reaction solution A, and 1 mLN-methylmorpholine (NMM) is added to adjust the pH value to 8-9. Stirring was carried out in an ice bath for 1h and at room temperature for 48h, and TLC (chloroform: methanol ═ 20:1) showed disappearance of 3-carboxyphenylboronic acid. Dicyclohexylurea (DCU) was filtered off and THF was distilled off under reduced pressure. The residue was dissolved in 50ml of Ethyl Acetate (EA), and the resulting solution was successively treated with saturated aqueous NaHCO3 solution, saturated aqueous NaCl solution, and 5% KHSO4Aqueous solution, saturated NaCl aqueous solution, saturated NaHCO3Washing the aqueous solution and saturated NaCl aqueous solution for three times, drying the ethyl acetate layer by using anhydrous Na2SO4, performing suction filtration under reduced pressure to remove a drying agent, and concentrating the filtrate under reduced pressure to be dry to obtain the compound 3-carboxyl phenylboronic acid-Orn (Boc) -OBzl.
2) Preparation of 3-carboxyphenylboronic acid-Orn (Boc) -OH:
stirring and dissolving 10mmol of 3-carboxyphenylboronic acid-Orn (Boc) -OBzl with a proper amount of methanol, adding a proper amount of Pd/C, keeping the reaction system sealed, pumping out air by using a tee joint, introducing hydrogen filled in a gas bag, pumping out air by using the tee joint, repeatedly replacing the air in the reaction system in such a way, finally staying the tee joint in a hydrogen introducing state, keeping a hydrogen environment at room temperature, stirring until a raw material point disappears, and monitoring by TLC. After the reaction is finished, Pd/C is removed by filtering under reduced pressure, and the filtrate is concentrated to be dry under reduced pressure to obtain a compound 3-carboxyphenylboronic acid-Orn (Boc) -OH.
3) Preparation of methyl 3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoate:
dissolving 3-carboxyphenylboronic acid-Orn (Boc) -OH 10mmol in 20mL of anhydrous Tetrahydrofuran (THF), adding N-hydroxybenzotriazole (HOBt)12mmol under ice bath condition, completely dissolving, slowly adding Dicyclohexylcarbodiimide (DCC)12mmol, and stirring for 30min to obtain reaction liquid A. Under the ice bath condition, 12mmol of methyl 4-aminobenzoate is dissolved in 20mL of anhydrous THF and added into the reaction liquid A, 1mL of N-methylmorpholine (NMM) is added, and the pH value is adjusted to 8-9. Stirred in ice bath for 1h, and further stirred at room temperature for 48h, TLC (chloroform: methanol ═ 20:1) showed disappearance of 3-carboxyphenylboronic acid-orn (boc) -OH. Filtering two ringsHexylurea (DCU), THF was evaporated under reduced pressure. The residue was dissolved in 50ml of Ethyl Acetate (EA), the solution obtained was in turn saturated NaHCO3Aqueous solution, saturated NaCl aqueous solution, 5% KHSO4Aqueous solution, saturated NaCl aqueous solution, saturated NaHCO3Washing with water solution and saturated NaCl water solution for three times, and treating ethyl acetate layer with anhydrous Na2SO4Drying, filtering under reduced pressure to remove the drying agent, and concentrating the filtrate under reduced pressure to dryness to obtain the compound 3-carboxyphenylboronic acid-Orn (Boc) -4-methyl aminobenzoate.
4) Preparation of 3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoic acid:
3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoic acid methyl ester was dissolved with an appropriate amount of methanol with stirring, the pH was adjusted to 13 with 2N NaOH solution in an ice-water bath, and the reaction was carried out for 6 hours in an ice-water bath, and TLC (chloroform: methanol ═ 20:1) showed disappearance of 3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoic acid methyl ester. With saturated KHSO4Adjusting pH of the reaction solution to neutral with water solution, concentrating under reduced pressure to dry, dissolving the residue with appropriate amount of saturated NaCl water solution, and dissolving with saturated KHSO4Adjusting pH of the aqueous solution to 2, extracting the water layer with ethyl acetate for 3 times, and extracting the ethyl acetate layer with anhydrous Na2SO4Drying, filtering under reduced pressure to remove the drying agent, and concentrating the filtrate under reduced pressure to dryness to obtain the compound 3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoic acid.
5) Preparation of 3-carboxyphenylboronic acid-Orn-4-aminobenzoic acid:
the 3-carboxyphenylboronic acid-Orn (Boc) -4-aminobenzoic acid was dissolved in a small amount of dry ethyl acetate, 4N HCl/EtOAc solution was added with stirring in an ice bath, TLC (EA: H2O: HAc ═ 4:1:2d) showed the disappearance of the starting material spot, the solution was drained with a water pump, anhydrous ether was added, the reaction was again drained with a water pump three times, and 3-carboxyphenylboronic acid-Orn-4-aminobenzoic acid was obtained.
6) Preparation of 3B-OH (3-carboxyphenylboronic acid-Orn (Cl) -4-aminobenzoic acid):
1mmol of 3-carboxyphenylboronic acid-Orn-4-aminobenzoic acid was dissolved with stirring in an appropriate amount of absolute methanol, 5mmol of ethyl 2-chloroacetimidoate hydrochloride were added in an ice-water bath, and the pH was adjusted to 10 with N, N-Diisopropylethylamine (DIPEA). Stirring was carried out at room temperature for 12 hours, TLC (EA: H2O: HAc ═ 4:1:2d) showed disappearance of 3-carboxyphenylboronic acid-Orn-4-aminobenzoic acid, concentration was carried out under reduced pressure until dryness, and purification was carried out by C18 column chromatography to obtain 3B-OH (3-carboxyphenylboronic acid-Orn (Cl) -4-aminobenzoic acid).
Example 2 Synthesis of CRGDV-Chitosan-4B
Synthesis of (I) chitosan-acryloyl chloride
First, chitosan (0.6g, 0.20mmol) and triethylamine (Et3N, 50. mu.L, 0.36mmol) were dissolved in 20mL of N, N-Dimethylformamide (DMF). After cooling at 0 deg.C, acryloyl chloride (8. mu.L, 0.10mmol) in 8mL of methylene chloride solution was added dropwise to the stirred solution. The reaction was carried out at room temperature for 24 hours and then dialyzed against distilled water (molecular weight cut-off of 700-1000 Da) for 48 hours. A pale yellow solid was obtained after lyophilization.
Synthesis of (di) chitosan-CRGDV
Chitosan-acryloyl chloride (0.3g, 0.10mmol) and CRGDV (98mg, 0.18mmol) were dissolved in 5mL of dimethyl sulfoxide and Et3N (10. mu.L, 0.07mmol) was added at room temperature. The reaction is stirred at room temperature for 12-24 hours and dialyzed against distilled water (MWCO: 700-1000 Da) for 48 hours. After lyophilization, a pale yellow solid was obtained.
(III) Synthesis of CRGDV-Chitosan-4B
Example 3 Synthesis of CRGDV-Chitosan-3B
Example 4 Synthesis of CRGDV-Chitosan-3B-OH
EXAMPLE 5 Synthesis of CRGDF-chitosan-4B
(I) Synthesis of Chitosan-CRGDF
Chitosan-acryloyl chloride (0.3g, 0.10mmol) and CRGDF (107mg, 0.18mmol) were dissolved in 5mL dimethyl sulfoxide (DMSO) and Et3N (10. mu.L, 0.07mmol) was added at room temperature. The reaction was stirred at room temperature for 24 hours and dialyzed against distilled water (MWCO: 1000Da) for 48 hours. After lyophilization, a pale yellow solid was obtained.
(II) Synthesis of CRGDF-chitosan-4B
EXAMPLE 6 Synthesis of CRGDF-chitosan-3B
Example 7 Synthesis of CRGDF-chitosan-3B-OH
Example 8 Synthesis of CRGDS-Chitosan-4B
Synthesis of (mono) chitosan-CRGDS
Chitosan-acryloyl chloride (0.3g, 0.10mmol) and CRGDS (104mg, 0.18mmol) were dissolved in 5mL dimethyl sulfoxide (DMSO) and Et3N (10. mu.L, 0.07mmol) was added at room temperature. The reaction was stirred at room temperature for 24 hours and dialyzed against distilled water (MWCO: 1000Da) for 48 hours. After lyophilization, a pale yellow solid was obtained.
Synthesis of (di) CRGDS-chitosan-4B
Example 9 Synthesis of CRGDS-Chitosan-3B
Example 10 Synthesis of CRGDS-Chitosan-3B-OH
The PAD4 inhibitor 3B-OH (10 μmol with chitosan-CRGDF (3.3 μmol) was dissolved in 5mL anhydrous DMSO the reaction was stirred at room temperature for 8h, then the reaction mixture was dialyzed against distilled water (MWCO: 1000Da) for 24h, then the resulting solution was lyophilized to obtain CRGDS-chitosan-3B-OH of 3B-OH: chitosan-CRGDS ═ 3: 1.
Structural characterization
Zeta potential and grain size
The Zeta potential and the particle size of the above partial products and intermediate products were tested, and the results are shown in table 1.
TABLE 1 Zeta potential and particle size of some of the products, intermediates
Zeta(mV) | Particle size (nm) | |
Chitosan | 27.3 | 233.2±23.36 |
Chitosan-CRGDV | 36.0 | 458.3±81.38 |
Chitosan-CRGDF | 31.7 | 413.6±133.5 |
Chitosan-CRGDS | 21.9 | 195.5±50.44 |
|
31.7 | / |
chitosan-CRGDV: 4B ═ 1:1 | / | / |
chitosan-CRGDV: 4B ═ 1:2 | 6.82 | 209.1±26.33 |
chitosan-CRGDV: 4B ═ 1:3 | 10.4 | 221.1±36.82 |
Chitosan-CRGDV: 4B: 1:4 | 27.8 | / |
chitosan-CRGDV: 4B ═ 1:5 | 12.2 | 262.3±37.43 |
Chitosan-CRGDV: 3B: 1:3 | 12.7 | 202.3±58.8 |
chitosan-CRGDV: 3B-OH ═ 1:3 | 30.3 | 188.9±63.09 |
In Table 1,/means that no valid data could be detected.
(II) Infrared Spectrum
The infrared spectrogram of chitosan is shown in FIG. 2;
the infrared spectrum of chitosan-CRGDV is shown in FIG. 3;
the infrared spectrogram of the chitosan-CRGDF is shown in FIG. 4;
the infrared spectrogram of chitosan-CRGDS is shown in FIG. 5;
the infrared spectrum of 4B is shown in FIG. 6;
the infrared spectrum of CRGDV-chitosan-4B is shown in FIG. 7;
the infrared spectrum of 3B is shown in FIG. 8;
the infrared spectrogram of CRGDV-chitosan-3B is shown in FIG. 9;
the infrared spectrum of 3B-OH is shown in FIG. 10;
the infrared spectrum of CRGDV-chitosan-3B-OH is shown in FIG. 11.
As can be seen from the above IR spectrogram, the IR spectrogram of chitosan in FIG. 2 is 1670cm more than the IR spectrogram of chitosan-CRGD series in FIGS. 3, 4 and 5-1The absorption of (2), here the characteristic absorption of carbonyl on amide bond, proves that chitosan is grafted with CRGD sequence peptide. In FIGS. 7, 9 and 11, the IR absorption changes in 1020cm compared with the IR spectra of chitosan-CRGDV in FIG. 3-1The absorption in the vicinity was significantly enhanced, demonstrating the successful attachment of the chitosan-CRGD series to the PAD4 inhibitor.
(III) nuclear magnetic resonance hydrogen spectrum
Process for preparing chitosan1HNMR map (300MHz, D2O) as shown in FIG. 12;
process for preparing chitosan-acryloyl chloride1H NMR chart (300MHz, D)2O) is shown in FIG. 13;
process for preparing chitosan-CRGDV1HNMR picture (300MHz, D)2O) is shown in FIG. 14;
process for preparing chitosan-CRGDF1H NMR chart (300MHz, D)2O) is shown in FIG. 15;
process for preparing chitosan-CRGDS1H NMR chart (300MHz, D)2O) is shown in FIG. 16;
preparation of CRGDV-chitosan-4B1H NMR chart (300MHz, D)2O) is shown in FIG. 17;
preparation of CRGDV-chitosan-3B1H NMR chart (300MHz, D)2O) is shown in FIG. 18;
method for preparing CRGDV-chitosan-3B-OH1H NMR chart (300MHz, D)2O) is shown in fig. 19.
(IV) Transmission Electron microscopy
The transmission electron micrograph (concentration: 0.1mg/mL) of chitosan is shown in FIG. 20;
the transmission electron micrograph (concentration: 0.1mg/mL) of chitosan-CRGDV is shown in FIG. 21;
the transmission electron micrograph (concentration: 0.1mg/mL) of chitosan-CRGDF is shown in FIG. 22;
the transmission electron micrograph (concentration: 0.1mg/mL) of chitosan-CRGDS is shown in FIG. 23;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 4B: 1 is shown in fig. 24;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 1:2 of 4B is shown in fig. 25;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 4B ═ 1:3 is shown in fig. 26;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 1:4 (4B) is shown in fig. 27;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 1:5 (4B) is shown in fig. 28;
and (3) chitosan: a transmission electron micrograph (0.1mg/mL) of 1:3 of 4B is shown in fig. 29;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 1:3 (3B) is shown in fig. 30;
chitosan-CRGDV: a transmission electron micrograph (0.1mg/mL) of 3B — OH ═ 1:3 is shown in fig. 31.
As can be seen from fig. 20, chitosan does not form nanoparticles with a uniform distribution of structural sizes. FIGS. 21-23 show that nanoparticles with uniform structural size distribution can be formed after chitosan is grafted with CRGDV/F/S. FIGS. 24-28 show that chitosan-CRGDV: when 4B is 1:4, nanoparticles with compact structure and uniform size can be formed, and as can be seen from fig. 27, the nanoparticles have a more compact inner layer and a more loose outer layer, indicating that CRGDV and PAD4 inhibitor 4B encapsulates chitosan to form nanoparticles. Fig. 29 shows that chitosan: when 4B is 1:3, nanoparticles having a compact structure and a uniform size can be formed. FIGS. 30 and 31 show that chitosan-CRGDV: 3B/3B-OH is 1:3, and can form nano particles with compact structure and uniform size.
Performance test
CRGDV-Chitosan-4B (Chitosan-CRGDV: 4B ═ 1:3) drug loading test
After 600. mu.g of 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl) was weighed using an analytical balance, 4mL of ultrapure water was dissolved to finally obtain a 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl) concentration of 150. mu.g/mL as a stock solution. Sequentially diluting to obtain 4B (4-carboxyphenylboronic acid-Orn (Cl) -NBzl) standard solutions with concentration gradients of 9.38, 18.75, 37.5, 75 and 150 mu g/mL respectively, and then respectively measuring ultraviolet absorption spectrograms to obtain standard curves. As shown in fig. 32.
The standard curve linear fit equation for 4B (4-carboxyphenylboronic acid-orn (cl) -NBzl) is y ═ 0.026x +0.0694, and R2 ═ 0.9982. 640 μ g of CRGDV-chitosan-4B (chitosan-CRGDV: 4B ═ 1:3) was weighed, and 4mL of ultrapure water was taken to dissolve the CRGDV-chitosan-4B so that the CRGDV-chitosan-4B concentration was finally 150 μ g/mL, the absorbance was measured to be 0.259, and when the concentration of 4B was calculated to be 7.3 μ g/mL, the drug loading amount of 4B in CRGDV-chitosan-4B was 7.3/150 ═ 4.7%. CRGDV-chitosan-4B (chitosan-CRGDV: 4B ═ 1:5)1370 μ g was weighed and dissolved in 4mL of ultrapure water until the CRGDV-chitosan-4B concentration reached 342.5 μ g/mL, the absorbance was measured as 1.334, and the 4B concentration was calculated as 48.6 μ g/mL, whereby the drug loading of 4B in CRGDV-chitosan-4B was 48.6/342.5 ═ 14.2%.
(II) in vitro tumor cell Activity
Evaluating the in vitro anti-cell proliferation activity of HCT-116 and S180 cells with different tested drugs, performing statistical analysis on the concentration of the tested compounds with inhibition rate, and calculating the IC of the positive drug and the nano drug-carrying system by using a regression analysis-probability statistical method in SPSS50The results are shown in Table 2.
TABLE 2 IC of the in vitro anti-cell-proliferation Activity of the test drugs50Value of
Test drug | HCT-116 | S180 |
DOX | 0.39±0.14 | 0.40±0.24 |
4B | 41.3±7.2 | 36.8±3.8 |
3B | 53.4±6.2 | 86.4±4.1 |
3B-OH | 67.5±4.2 | 73.2±6.9 |
CRGDV-Chitosan | ND | ND |
CRGDV-Chitosan-4B | 4.7±1.4 | 6.2±1.8 |
CRGDV-Chitosan-3B | 15.6±1.3 | 18.9±3.4 |
CRGDV-Chitosan-3B-OH | 21.3±3.8 | 23.9±4.3 |
CRGDF-chitosan | ND | ND |
CRGDF-chitosan-4B | 6.8±2.1 | 9.4±2.5 |
CRGDF-chitosan-3B | 20.2±3.1 | 28.7±4.2 |
CRGDF-chitosan-3B-OH | 23.5±2.9 | 29.3±4.6 |
CRGDS-chitosan | ND | ND |
CRGDS-Chitosan-4B | 10.7±2.3 | 20.9±4.9 |
CRGDS-Chitosan-3B | 21.6±1.9 | 29.4±5.3 |
CRGDS-Chitosan-3B-OH | 26.4±1.5 | 34.1±4.5 |
Note: ND means not found, n is 9.
As can be seen from Table 2, the PAD4 inhibitor loaded on the CRGD sequence peptide modified chitosan provided by the invention has good in vivo biological activity.
(III) evaluation of in vivo antitumor Activity
Negative control group: normal Saline (NS), 10 per group, administered by tail vein injection; positive control group: adriamycin (DOX), 10 in each group, with the dosage of 2.0 mu mol/kg, and the administration route is intraperitoneal injection; test group: PAD4 inhibitor 4B, CRGDV-chitosan, CRGDV-chitosan-4B, 5 groups, 10 each, 4B dose of 10.0 μmol/kg, CRGDV-chitosan-4B group 4B dose of 2.0 μmol/kg, administration route of tail vein injection.
Experimental procedure
The tumor source used by the transplanted mouse S180 sarcoma model is S180 mouse fibrosarcoma cells, which are purchased from animal experiment center of department of medicine of Beijing university and maintained by self passage. Inoculating S180 mouse fibrosarcoma cells into an abdominal cavity of an SPF male ICR mouse, carrying out self-passage, anesthetizing the mouse with S180 ascites tumor after passage for one week with a proper amount of ether, removing the neck, killing the mouse, soaking and sterilizing the mouse in 75% alcohol for 1min, then splitting the abdominal cavity of the mouse, collecting ascites S180 tumor liquid, centrifuging the tumor liquid for 10min at 1000rpm, discarding the supernatant, washing with normal saline to remove non-cell fragments, tissues and floating blood, fully mixing to obtain S180 cell suspension, diluting to a certain multiple, and uniformly mixing with freshly prepared 0.2% trypan blue in at a volume ratio of 9:1 for dyeing. Live cells will not be stained blue, while dead cells will be stained pale blue.
Counting by using an erythrocyte counting plate, and calculating the cell concentration and the cell survival rate according to the following formulas:
cell concentration (cell number/mL) 4 viable cells in large grid/4X 104X dilution fold cell survival rate ═ viable cell number/(viable cell number + dead cell number) × 100%
Diluting cell suspension with survival rate of more than 90% to 2 × 10 with physiological saline7And (2) each mL, wherein inoculation of the experiment should be completed as soon as possible, when inoculation is performed, the mouse is grabbed by the left hand to be fixed, the right hand-held syringe is punctured into the right armpit of the mouse to the depth of about 2mm below the skin, a small cavity is separated by using a needle in a blunt manner, 0.2mL of prepared cell suspension is injected, and the cell suspension is mixed uniformly before each injection. And completing the establishment of the animal model. After the model is established, the mice are observed every day, and are grouped after the solid tumors with the sizes of soybean grains are visible in the armpits of most of the mice, the mice in each group are randomly grouped on the 5 th day after inoculation, so that the sizes of the tumors of the mice in each group are evenly distributed, the administration is started on the same day, 1 time per day, and the 7 th administration is performed from the 11 th day. The mice were removed 24h after the last administration, and each group of mice was weighed and anesthetized with etherRemoving eyeball to take blood, then removing neck to kill, fixing mouse axillary solid tumor growth part with forceps with left hand, cutting skin with scissors with right hand, fully exposing tumor tissue, performing blunt separation along skin and upper limb, taking out tumor tissue, and weighing. Then, the heart, liver, spleen, kidney, brain and other organs of the mouse are sequentially dissected and taken out for weighing.
Results and analysis of the experiments
In situ tumor tissue mass is expressed as mean ± SD g, and statistical comparisons between groups were made by t-test. The inhibition rate is [ (average value of tumor weights of negative control group-average value of tumor weights of test compound)/(average value of tumor weights of negative control group)/] × 100%.
The results of evaluating the tumor proliferation inhibitory activity in test drug bodies in the transplanted mouse S180 sarcoma model are shown in Table 3.
TABLE 3 evaluation of tumor proliferation inhibitory Activity in test drug bodies
Test drug | Tumor weight (g) | Inhibition ratio (%) |
NS | 1.91±0.55 | |
DOX | 0.84±0.14a | 56.0% |
4B | 1.34±0.22a | 29.8% |
3B | 1.45±0.42a | 24.1% |
3B-OH | 1.52±0.34a | 20.4% |
CRGDV-Chitosan | 1.87±0.56 | 2.1% |
CRGDV-Chitosan-4B | 0.97±0.43a | 49.2% |
CRGDV-Chitosan-3B | 1.31±0.33a | 31.4% |
CRGDV-Chitosan-3B-OH | 1.43±0.41a | 25.1% |
CRGDF-chitosan | 1.81±0.55 | 5.2% |
CRGDF-chitosan-4B | 1.09±0.44a | 42.9% |
CRGDF-chitosan-3B | 1.37±0.34a | 28.3% |
CRGDF-chitosan-3B-OH | 1.52±0.37a | 20.4% |
CRGDS-Chitosan | 1.77±0.39 | 7.3% |
CRGDS-Chitosan-4B | 1.27±0.35a | 33.5% |
CRGDS-Chitosan-3B | 1.46±0.39a | 23.6% |
CRGDS-Chitosan-3B-OH | 1.62±0.54 | 15.2% |
Note: dox tail vein 0.2mg/kg a
4B,3B and 3B-OH tail vein 10.0. mu. mol/kg
CRGDV/F/S-Chitosan-4B, CRGDV/F/S-Chitosan-3B and CRGDV/F/S-Chitosan-3B-OH, 2.0. mu. mol/kg
CRGDV/F/S-chitosan 0.2mg/kg
n-10, by t test, a: p <0.01 compared to NS;
as can be seen from table 3, the CRGD sequence peptide-modified chitosan-loaded PAD4 inhibitor provided by the present invention has good in vivo tumor proliferation inhibition activity.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (8)
1. A PAD4 inhibitor loaded on CRGD sequence peptide modified chitosan, which comprises a CRGD sequence peptide modified chitosan carrier and a PAD4 inhibitor loaded on the surface of the CRGD sequence peptide modified chitosan carrier;
cysteine in the CRGD sequence peptide is connected to the chitosan surface through acryloyl chloride;
the CRGD sequence peptide comprises one or more of CRGDV, CRGDS and CRGDF; the CRGDV is cysteine-arginine-glycine-aspartic acid-valine, the CRGDS is cysteine-arginine-glycine-aspartic acid-phenylalanine, the CRGDF is cysteine-arginine-glycine-aspartic acid-serine;
the PAD4 inhibitor comprises one or more of PAD4 inhibitor 4B, PAD4 inhibitor 3B, PAD4 inhibitor 3B-OH;
the structural formula of the PAD4 inhibitor 4B is shown as formula 1:
the structural formula of the PAD4 inhibitor 3B is shown as a formula 2:
the PAD4 inhibitor 3B-OH has a structural formula shown in formula 3:
2. the CRGD-sequence peptide modified chitosan loaded PAD4 inhibitor of claim 1, wherein the PAD4 inhibitor loading of the CRGD-sequence peptide modified chitosan loaded PAD4 inhibitor is 12-18 wt%.
3. The preparation method of the PAD4 inhibitor loaded on the CRGD sequence peptide modified chitosan of any one of claims 1-2, comprising the following steps:
(1) mixing chitosan, acryloyl chloride, a first acid-binding agent and a first organic solvent, and carrying out nucleophilic substitution reaction to obtain acryloyl chloride modified chitosan;
(2) mixing the chitosan modified by acryloyl chloride, the CRGD sequence peptide, a second acid-binding agent and a second organic solvent, and carrying out Michael addition reaction to obtain a CRGD sequence peptide modified chitosan carrier;
(3) and stirring and mixing the CRGD sequence peptide modified chitosan carrier, the PAD4 inhibitor and a third organic solvent to obtain the PAD4 inhibitor loaded by the CRGD sequence peptide modified chitosan.
4. The method according to claim 3, wherein the molar ratio of chitosan to acryloyl chloride is 1.5 to 3:1, and the molar ratio of chitosan to CRGD sequence peptide is 1 to 2: 1.8.
5. The method of claim 3, wherein the molar ratio of chitosan to PAD4 inhibitor is 1:1 to 5.
6. The preparation method according to claim 3, wherein the nucleophilic substitution reaction time is 12-24 hours.
7. The preparation method of claim 3, wherein the Michael addition reaction time is 12-24 hours.
8. Use of the CRGD sequence peptide-modified chitosan-loaded PAD4 inhibitor described in any one of claims 1 to 2 or the CRGD sequence peptide-modified chitosan-loaded PAD4 inhibitor prepared by the preparation method described in any one of claims 3 to 7 in preparation of an anti-tumor drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110652104.0A CN113350296B (en) | 2021-06-11 | 2021-06-11 | PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110652104.0A CN113350296B (en) | 2021-06-11 | 2021-06-11 | PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113350296A CN113350296A (en) | 2021-09-07 |
CN113350296B true CN113350296B (en) | 2022-07-15 |
Family
ID=77533869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110652104.0A Active CN113350296B (en) | 2021-06-11 | 2021-06-11 | PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113350296B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101690823A (en) * | 2009-11-03 | 2010-04-07 | 首都医科大学 | Method for preparing RGDV-containing cytosine arabinoside conjugate pharmacosome and application as antitumor agent |
CN105884862A (en) * | 2014-12-16 | 2016-08-24 | 首都医科大学 | RGD tetrapeptide modified beta-carboline acyl-tryptophan and preparation, nanostructure, activity and application thereof |
CN112679535A (en) * | 2021-01-06 | 2021-04-20 | 首都医科大学 | Small molecule PAD4 inhibitor and preparation method and application thereof |
-
2021
- 2021-06-11 CN CN202110652104.0A patent/CN113350296B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101690823A (en) * | 2009-11-03 | 2010-04-07 | 首都医科大学 | Method for preparing RGDV-containing cytosine arabinoside conjugate pharmacosome and application as antitumor agent |
CN105884862A (en) * | 2014-12-16 | 2016-08-24 | 首都医科大学 | RGD tetrapeptide modified beta-carboline acyl-tryptophan and preparation, nanostructure, activity and application thereof |
CN112679535A (en) * | 2021-01-06 | 2021-04-20 | 首都医科大学 | Small molecule PAD4 inhibitor and preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles;Hee Dong Han等;《Clinical Cancer Research》;20110801;第16卷(第15期);3910-3922页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113350296A (en) | 2021-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110237035B (en) | Active targeting amphiphilic polypeptide nano-drug carrier and preparation and application thereof | |
EP3459546B1 (en) | Multi-arm polymeric targeting anti-cancer conjugate | |
CN103044523B (en) | Dexamethasone-RGD polypeptide conjugate, preparation method thereof and application | |
CN103083680B (en) | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition | |
US9415114B2 (en) | Conformations of divergent peptides with mineral binding affinity | |
CN101538312A (en) | Preparation and applications of RGD-fatty amine series compound as tumor targeting vector material | |
CN103550781A (en) | Self-assembled dendrimer drug carrier, and preparation method and application thereof | |
CN104650194A (en) | Peptide dentritic macromolecular drug and preparation method and application thereof | |
AU2018255458B2 (en) | Multi-arm targeted anti-cancer conjugate | |
CN115518165A (en) | Application of PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan in preparation of anti-tumor metastasis drugs | |
CN108727583B (en) | Multi-arm targeted anticancer conjugate | |
CN106512021A (en) | Paclitaxel-loading asymmetric dendrimer nanometer drug carrier system and preparation method thereof | |
CN106397765A (en) | Vitamin E-modified polyethyleneimine (PEI) derivative, and synthetic method and application thereof | |
CN113350296B (en) | PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan and preparation method and application thereof | |
CN111494642A (en) | Self-assembly material for in-situ construction of artificial extracellular matrix and preparation method and application thereof | |
CN110152013B (en) | Pectin-adriamycin conjugate and preparation method and application thereof | |
CN113995846B (en) | Polyethylene glycol coupling drug synergist and preparation method and application thereof | |
CN105585611B (en) | Octapeptide modified dexamethasone, preparation, nanostructure and application thereof | |
CN112266409B (en) | Etoposide self-assembly nanofiber polypeptide, preparation method and application | |
CN110418653B (en) | Pectin-adriamycin conjugate and preparation method and application thereof | |
CN109701013B (en) | Targeted nano drug delivery system and preparation method thereof | |
CN118059066A (en) | Ferric oxide-chitosan-PAD 4 inhibitor nano-drug and preparation method and application thereof | |
CN110772643B (en) | Alpha-tocopherol polyethylene glycol succinate modified cardiac glycoside compound prodrug | |
CN115068624B (en) | Peptide dendrimer drug-carrying system and preparation method and application thereof | |
CN112979881B (en) | Macromolecules, compositions and methods for enhancing anticancer drug uptake |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |